“Laboratory Parameters in Adolescent Patients Aged 12–17 with Moderate-to-Severe Atopic Dermatitis Treated with Tralokinumab Up to Week 52: Results from the Phase 3 ECZTRA 6 Trial”, J of Skin, vol. 8, no. 1, p. s323, Jan. 2024, doi: 10.25251/skin.8.supp.323.